OncoMatch/Clinical Trials/NCT06939127
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
Is NCT06939127 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy and Adjuvant tislelizumab for nsclc (non-small cell lung cancer).
Treatment: Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy · Adjuvant tislelizumab — This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy in patients with resectable stage II-IIIB non-small cell lung cancer (NSCLC). The study consists of a screening phase, a treatment phase (including the neoadjuvant stage, surgery, and adjuvant stage), a safety follow-up period, and a survival follow-up period.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR mutation
Known EGFR mutations [excluded]. For non-squamous NSCLC, EGFR mutation status must be confirmed locally or centrally if unknown.
Excluded: ALK fusion
Known...ALK translocations [excluded].
Disease stage
Required: Stage II, IIIA, IIIB (AJCC 9th edition)
Excluded: Stage IV, IIIC
Histologically confirmed stage II-IIIB NSCLC (AJCC 9th edition). Locally advanced, unresectable disease, regardless of stage or metastasis (stage IV) [excluded]. Patients with mediastinal lymph node involvement on CT must undergo sampling for clinical staging to exclude stage IIIB/C.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Lab requirements
Cardiac function
adequate cardiopulmonary function for radical surgical resection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06939127 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK fusion is an exclusion criterion.
What disease stage is eligible?
Stage II or IIIA or IIIB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages